German genetic diagnostics company CeGaT has been growing rapidly over the last year to accommodate increasing demand for next-generation sequencing-based diagnostic tests in Germany and beyond.

The firm's portfolio of gene panels for inherited disorders has expanded to 14 disease areas, including hereditary cancer. The number of panels, many of which it developed in collaboration with academic partners, has nearly doubled to about 120. CeGaT also has started offering diagnostic exome sequencing, mainly of parent-child trios.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.